back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-01-13 15:43 Tx date 2024-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Common Shares
57 - Exercise of rights
|
$22,238
+20,784 vol $1.07 each |
123,209 | |
| Filed 2024-01-13 15:42 Tx date 2024-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Restricted Share Units
57 - Exercise of rights
|
$-22,238.88
-20,784 vol $1.07 each |
75,684 | |
| Filed 2023-11-18 15:03 Tx date 2023-11-15 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Common Shares
57 - Exercise of rights
|
$3,466
+3,333 vol $1.04 each |
102,425 | |
| Filed 2023-11-18 15:02 Tx date 2023-11-15 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Restricted Share Units
57 - Exercise of rights
|
$-3,466.32
-3,333 vol $1.04 each |
96,468 | |
| Filed 2023-09-15 17:45 Tx date 2023-09-12 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Options
50 - Grant of options
|
+72,000 vol |
72,000 | |
| Filed 2023-09-15 17:44 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-01-14 15:39 Tx date 2023-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
$12,261
+20,783 vol $0.59 each |
99,092 | |
| Filed 2023-01-14 15:37 Tx date 2023-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Restricted Share Units
57 - Exercise of rights
|
$-12,261.97
-20,783 vol $0.59 each |
99,801 | |
| Filed 2022-12-01 22:25 Tx date 2022-11-28 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$22,800
+47,500 vol $0.48 each |
68,918 | |
| Filed 2022-12-01 22:23 Tx date 2022-11-28 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
$-22,800
-47,500 vol $0.48 each |
110,000 | |
| Filed 2022-11-19 11:54 Tx date 2022-11-15 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Common Shares
57 - Exercise of rights
|
$1,599
+3,333 vol $0.48 each |
78,309 | |
| Filed 2022-11-19 11:53 Tx date 2022-11-15 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Restricted Share Units
57 - Exercise of rights
|
$-1,599.84
-3,333 vol $0.48 each |
120,584 | |
| Filed 2022-11-19 11:46 Tx date 2022-11-15 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+24,000 vol |
94,000 | |
| Filed 2022-01-13 13:39 Tx date 2022-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
57 - Exercise of rights
|
+20,783 vol |
74,976 | |
| Filed 2022-01-13 13:36 Tx date 2022-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Restricted Share Units
57 - Exercise of rights
|
-20,783 vol |
123,917 | |
| Filed 2021-11-19 22:39 Tx date 2021-11-15 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Restricted Share Units
56 - Grant of rights
|
+20,000 vol |
144,700 | |
| Filed 2021-06-06 16:28 Tx date 2021-06-02 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$182,672
+41,296 vol $4.42 each |
54,193 | |
| Filed 2021-03-06 12:48 Tx date 2021-03-03 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$7,065
+1,372 vol $5.15 each |
12,897 | |
| Filed 2021-03-03 20:17 Tx date 2021-03-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$21,128
+3,994 vol $5.29 each |
11,525 | |
| Filed 2021-02-27 17:00 Tx date 2021-02-23 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$23,739
+3,721 vol $6.38 each |
7,531 | |
| Filed 2021-01-15 18:58 Tx date 2021-01-11 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Restricted Share Units
56 - Grant of rights
|
+124,700 vol |
124,700 | |
| Filed 2021-01-15 18:57 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-17 18:45 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
37 - Stock split or consolidation
|
-1,417,500 vol |
157,500 | |
| Filed 2020-12-17 18:44 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-630,000 vol |
70,000 | |
| Filed 2020-12-17 18:43 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
37 - Stock split or consolidation
|
-34,290 vol |
3,810 | |
| Filed 2020-12-17 18:42 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-192,763 vol |
21,418 | |
| Filed 2020-06-06 14:35 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$28,999
+200,000 vol $0.145 each |
214,181 | |
| Filed 2020-06-06 14:34 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-29,000
-200,000 vol $0.145 each |
700,000 | |
| Filed 2019-11-28 13:26 Tx date 2019-11-28 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+475,000 vol |
1,575,000 | |
| Filed 2018-10-05 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-10-05 Tx date 2018-10-03 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
97 - Other
|
+1,100,000 vol |
1,100,000 | |
| Filed 2018-09-19 Tx date 2018-09-19 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,450
+35,000 vol $0.27 each |
38,100 | |
| Filed 2017-04-03 Tx date 2017-03-31 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$120,000
+600,000 vol $0.20 each |
900,000 | |
| Filed 2016-03-11 Tx date 2016-03-09 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$43,500
+300,000 vol $0.145 each |
300,000 | |
| Filed 2016-03-11 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-03-11 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
3,100 | ||
| Filed 2016-03-11 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
14,181 | ||
| Filed 2016-03-11 Tx date 2015-12-01 |
$ATE
Antibe Therapeutics Inc. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-06-12 Tx date 2015-06-08 |
$QRM
Quest Rare Minerals Ltd. |
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
96,000 |